First Time Loading...

Hualan Biological Engineering Inc
SZSE:002007

Watchlist Manager
Hualan Biological Engineering Inc Logo
Hualan Biological Engineering Inc
SZSE:002007
Watchlist
Price: 20.07 CNY 2.14% Market Closed
Updated: May 20, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Hualan Biological Engineering Inc

Revenue
5.2B CNY
Cost of Revenue
-1.7B CNY
Gross Profit
3.6B CNY
Operating Expenses
-1.8B CNY
Operating Income
1.8B CNY
Other Expenses
-368.4m CNY
Net Income
1.4B CNY

Margins Comparison
Hualan Biological Engineering Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Hualan Biological Engineering Inc
SZSE:002007
36.6B CNY
68%
34%
27%
US
Abbvie Inc
NYSE:ABBV
291.9B USD
66%
29%
11%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
66%
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD
87%
41%
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
108.4B USD
86%
30%
29%
AU
CSL Ltd
ASX:CSL
134.3B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
84.6B USD
76%
32%
2%
US
Moderna Inc
NASDAQ:MRNA
54.2B USD
22%
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
33.8B USD
75%
22%
12%
KR
Celltrion Inc
KRX:068270
38.7T KRW
48%
30%
25%
Country CN
Market Cap 36.6B CNY
Gross Margin
68%
Operating Margin
34%
Net Margin
27%
Country US
Market Cap 291.9B USD
Gross Margin
66%
Operating Margin
29%
Net Margin
11%
Country US
Market Cap 168.4B USD
Gross Margin
66%
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 115.5B USD
Gross Margin
87%
Operating Margin
41%
Net Margin
39%
Country US
Market Cap 108.4B USD
Gross Margin
86%
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 134.3B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 84.6B USD
Gross Margin
76%
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 54.2B USD
Gross Margin
22%
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 33.8B USD
Gross Margin
75%
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 38.7T KRW
Gross Margin
48%
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Hualan Biological Engineering Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Hualan Biological Engineering Inc
SZSE:002007
36.6B CNY
13%
9%
13%
13%
US
Abbvie Inc
NYSE:ABBV
291.9B USD
56%
4%
15%
13%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD
24%
19%
23%
33%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
108.4B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
134.3B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
84.6B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
54.2B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
33.8B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
38.7T KRW
5%
4%
6%
4%
Country CN
Market Cap 36.6B CNY
ROE
13%
ROA
9%
ROCE
13%
ROIC
13%
Country US
Market Cap 291.9B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
13%
Country US
Market Cap 168.4B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 115.5B USD
ROE
24%
ROA
19%
ROCE
23%
ROIC
33%
Country US
Market Cap 108.4B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 134.3B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 84.6B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 54.2B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 33.8B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 38.7T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More